Thu. Nov 25th, 2021
    0 0
    Spread the love
    Click to rate this post!
    [Total: 1 Average: 5]
    Read Time:16 Minute, 54 Second

    Electrochemical DNA sensor on a chip detects what caused UTIs faster

    An electrochemical sensor that can quickly find out whether a urinary tract infections (UTI) is caused by bacteria or not could become the latest weapon against antibiotic resistance.

    Researchers at McMaster University in Canada have created a test on a chip that uses synthetic nucleic acid probes – RNA-cleaving DNAzymes (RCDs) – to detect Escherichia coli. ‘This is the first example of a DNAzyme test combined with electrical readout that is evaluated and proven using clinical samples,’ comments Leyla Soleymani, one of the scientists who led the study. Because the test avoids the need to culture bacteria, it returns results in less than an hour.

    medicine for uti

    The test targets E. coli because it causes the vast majority of UTIs, explains Soleymani’s colleague Yingfu Li. Usually, it takes more than 18 hours to diagnose a bacterial infection, Soleymani adds, meaning that doctors might not prescribe the most effective antibiotics – a hotbed for creating antibiotic-resistant bacteria. If tests were quicker, physicians could be more precise.

    Researchers have therefore previously developed faster tests. For example, some systems have used the polymerase chain reaction to detect the bacteria’s genetic material – but these approaches are complex and costly.

    Now, the researchers built on RCD sensors previously developed by Li’s team. His group has a library of synthetic DNA molecules from which they can select one the ones that recognise specific substances. The RCDs are self-cleaving oligonucleotides that include a DNA barcode, which they release when they recognise their target substance. The new sensor uses RCDs that identifies molecules released by heating urine samples containing E. coli. The RCDs release DNA barcodes bound to methylene blue dye molecules, which electrochemical biosensors can detect.

    Li, Soleymani and their colleagues attached their RCDs to a star-shaped, nanostructured electrode on a small chip that holds liquid samples. When a solution containing molecules released by E. coli reaches the electrode, the RCDs release their barcodes, generating an electrical signal. The barcodes diffuse to another nearby star-shaped electrode containing a DNA sequence designed to bind with them, which generates another electrical signal. This electrochemical test has ‘a really high sensitivity’, says Soleymani, thanks in part to the nanostructured electrodes’ high surface area.

    Peiying Hong from the King Abdullah University of Science and Technology in Saudi Arabia, notes that the system has a high signal-to-noise ratio. That ‘allows them to differentiate E. coli in a conclusive manner relative to the other bacterial non-targets’, Hong says. She notes that the test is unusual in having an electrical output rather than changing colour. ‘One can read the results directly from a portable app or electronic device,’ Hong observes. ‘However, the device is able to obtain only qualitative measurements since the signals do not respond linearly to the increase in bacterial load.’

    The McMaster team now wants to expand on the system to analyse several different bacteria, including antibiotic resistant ones, says Soleymani. ‘We are also looking for a commercialisation partner for bringing this test to the market,’ she adds.

    Fairfield doctor: Antibiotic overuse creates super infections and ‘super-superbugs’

    Jul. 7—An infectious disease specialist with Mercy Health-Fairfield Hospital is cautioning both his fellow doctors and patients that overuse of antibiotics simply when bacteria are found in someone’s urine is not only unnecessary and wasteful but also can be dangerous to the patients’ lives.

    Dr. Dheeraj Goyal studied 251 adult patients with urinary tract infections who were admitted to hospitals because of highly antibiotic resistant bacteria “superbugs” known as ESBL over a 15-year period and compared them with 251 adult patients admitted with non-ESBL infections of the urinary tract.

    “The key here is just to avoid antibiotics, unless they are needed,” Goyal said in an interview. “Having the symptoms of infection is very important.”

    Over-prescribing can lead to infections that are not affected by any drugs, sometimes leading to patients’ deaths. Since 2018 in Butler County alone, there have been 25 cases of theseCP-CRE, which Goyal calls the “superbugs of superbugs,” and the Centers for Disease Control and Prevention in an 2019 report listed them as an “urgent threat” and noted also goes by the name of “nightmare bacteria.”

    Sometimes after doctors conduct urine tests for other diseases, if bacteria levels in the urine are present, they prescribe antibiotics to prevent urinary tract infections even though bacteria in the urine is very common in older people and post-menopausal women, he said.

    Other times, when patients themselves see test results showing bacteria in the urine, they press their doctors for antibiotics, even when they have no symptoms of urinary tract infections, Goyal said.

    While patients may want antibiotics in such cases, “Ninety-nine percent of the time, these people will not develop symptoms,” he said. “If you’re not having symptoms, you’re just harboring bacteria.”

    Symptoms of urinary tract infections include urinating frequently, pain or burning when urinating, blood in the urine, pelvic or lower abdominal pain, back pain, nausea, vomiting or fever.

    Story continues

    When patients develop ESBLs, they usually have to spend days in the hospital receiving intravenous infusions of antibiotics and in isolation. That has become quite common.

    “Typically, there are three or four of these ESPL UTI (urinary tract infection) patients almost every day, unfortunately,” he said. “And that’s just at Mercy Health — Fairfield Hospital.

    “These can also cause outbreaks in the hospitals,” so patients are placed in isolation, with the staff wearing special gowns and gloves, discarding their clothing before they leave the rooms.

    When someone has a CP-CRE — he comes across a pan-resistant patient every couple of years or so — “in those cases, unfortunately, you have to give up,” he said. Sometimes the patient survives, and sometimes not.

    Goyal recommends these things: — Patients should avoid requesting a screening urine culture unless there are symptoms of a urinary tract infections. — Doctors should resist patient pressure. He understands that’s difficult. He tells patients it only takes him one minute to write them a prescription, but 15 minutes to explain why he won’t do so.

    During the 1940s and 1950s, penicillin was the antibiotic used to treat everything, “and now, most of the bacteria is penicillin-resistant, because it was so overused,” he said.

    Antibiotics that were effective 10 to 15 years ago now are not nearly as effective as they once were, he said.

    “CP-CREs are difficult to treat because they are resistant to standard drugs as well as some of our ‘drugs of last resort,'” said Jennifer Bailer, Butler County’s health commissioner. “They are particularly contagious and have spread to all fifty states since their first identification in the U.S.”

    Ohio health departments first were required to report them in 2018.

    In Montgomery County, since those reporting requirements were set, the county saw six cases in 2018; 13 in 2019; 37 in 2020 and 20 so far this year, said Michael Dohn, medical director at Public Health — Dayton & Montgomery County.

    In Hamilton County, there were 17 cases in 2019 according to Hamilton County Public Health spokesman Mike Samet, who did not provide information for all the years since 2018.

    Uncomplicated Urinary Tract Infection Market to Witness Growth at a CAGR of 10.8% During the Study Period 2018-2030 | DelveInsight

    LAS VEGAS, July 5, 2021 /PRNewswire/ — DelveInsight’s Uncomplicated Urinary Tract Infection (uUTI) Market report offers a comprehensive coverage of the current treatment practices, pipeline drugs, Uncomplicated Urinary Tract Infection market share of the individual therapies, current and forecasted uUTI market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

    Some of the salient points featured in the Uncomplicated Urinary Tract Infection Market report: Uncomplicated Urinary Tract Infection typically affects individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. Recurrent UTI (rUTI) are at least 2 infections within 6 months or at least 3 infections within 1 year. rUTI in women is caused by uropathogens that adhere well to the uroepithelial cells.The Uncomplicated Urinary Tract Infection treated cases in the 7MM bifurcated into first-line and recurrent pools were reported to be approximately 18.4 million and 6.6 million in 2020, respectively.Antibiotics are the gold standard in the Urinary Tract Infection treatments market.AUA/CUA/SUFU guidelines recommend nitrofurantoin, TMP-SMX, and fosfomycin as the first-line therapy for the treatment of symptomatic Urinary Tract Infections in women. Primarily because of increasing bacterial resistance to other agents, the use of fosfomycin in the United States is starting to grow in Uncomplicated Urinary Tract Infections. However, the poor bioavailability of oral fosfomycin limits its use in patients who are critically ill. The blockbuster antibacterial drugs, such as azithromycin, ceftriaxone, ciprofloxacin, levofloxacin, were introduced over the last 20 years, many of which are now off-patent and have become even lower-priced; and this will pose significant price pressure on the upcoming emerging therapies.Key players, such as GlaxoSmithKline, Fimbrion Therapeutics, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, among several others, are devotedly working in the sphere wheeling the Uncomplicated Urinary Tract Infection market forward. The emerging Uncomplicated Urinary Tract Infection therapies under development, such as Gepotidacin, GSK3882347, Uromune, ExPEC10V, among others, are anticipated to provide efficient therapeutic approaches with a novel mechanism of action for the treatment of patients.GSK’s GSK2140944 (Gepotidacin) is in the late-stage uUTI trial, and the results are expected from the ongoing phase III trial by 2022. The drug is among one of the few in the late-stage developmental phases that give it a leg-up over the other therapies. Among all the emerging therapies in the Uncomplicated Urinary Tract Infection Market, GSK2140944 is expected to emerge as a groundbreaker owing to the targeting of the broader pool in ongoing pivotal trial and also the company is evaluating the potential against nitrofurantoin as well which will provide an edge over the other therapies if the drug is able to show the better clinical profile.The Uncomplicated Urinary Tract Infection market size is expected to soar at an exponential growth rate attributable to the emergence of novel therapeutic options, approaches to tackle antibiotic resistance, antibiotic stewardship programs, non-antibiotic prophylaxis strategies along with an increase in the Urinary Tract Infections diagnosis due to lifestyle alterations.

    Discover more about therapy set to grab substantial market share @ Uncomplicated Urinary Tract Infection Market Share

    Uncomplicated Urinary Tract Infection: Overview 

    Urinary Tract Infection (UTI) is the most common bacterial infection caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. It can infect any part of the urinary system. While Uncomplicated Urinary Tract Infection (uUTI) occurs most commonly in young, sexually active women with a normal, unobstructed genitourinary tract, no history of recent instrumentation, and symptoms confined to the lower urinary tract. 

    Recurrent UTI is defined as at least two infections within 6 months or at least three infections within 1 year. The recurrence of a UTI may be relapse (i.e., caused by the same uropathogen) or re-infection (i.e., caused by different uropathogens). Most recurrences are likely re-infection rather than relapse. The frequency of infections caused by Proteus, Pseudomonas, Klebsiella, Enterobacter spp., antibiotic-resistant E. coli, enterococci, and staphylococci increases significantly with Recurrent Complicated UTI involving structural abnormalities.

    Discover more about the infection, causes, signs & symptoms, and diagnosis @  Uncomplicated Urinary Tract Infection Signs & Symptoms and Diagnosis

    Uncomplicated Urinary Tract Infection Epidemiology Segmentation 

    DelveInsight estimates that the year 2020 observed approximately 35.3 million Uncomplicated Urinary Tract Infection cases in the 7MM, which are further expected to grow during the study period 2018–2030. Moreover, among the age groups studied, namely 18-29 years, 30–49 years, 50–69 years, and ≥70 years, around 60% uUTI cases are observed in the patients with age 18-49 years because of high sexual activity and other health-related factors

    The Uncomplicated Urinary Tract Infection market report puts forward the epidemiological analysis for the study period 2018-30 in the 7MM segmented into: Total Uncomplicated Urinary Tract Infection Cases Total Diagnosed Uncomplicated Urinary Tract Infection Cases Total Age-specific Uncomplicated Urinary Tract Infection Cases Total Pathogen-specific Uncomplicated Urinary Tract Infection Cases Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection 

    Download sample report to understand which demographic factors are guiding the uUTI epidemiology trends @ Uncomplicated Urinary Tract Infection Epidemiological Insights

    Uncomplicated Urinary Tract Infection Therapy Market 

    The present Uncomplicated Urinary Tract Infection Therapy Market is dominated by antibiotics. Antibiotics are usually used to manage UTIs because they regulate the duration and severity of symptoms and complications with the ultimate aim to get rid of infecting organisms.

    Some of the most commonly prescribed antibiotics in the Uncomplicated Urinary Tract Infection include the combination drug trimethoprim and sulfamethoxazole, trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine. 

    Geography-wise Uncomplicated Urinary Tract Infection Therapy Market 

    Increasing bacterial resistance is a huge challenge in the treatment market that has limited the use of available treatment options. Owing to this, the use of fosfomycin in the United States appeared to have gained traction over other available agents. However, the poor bioavailability of oral fosfomycin limits its use in patients who are critically ill. 

    Moving to the EU-5 Uncomplicated Urinary Tract Infection Drug Market, the first-choice empiric antibiotic treatment varies considerably among the countries. While Germany’s uUTI therapy market is dominated by Nitrofurantoin and pivmecillinam, in Spain, fluoroquinolones and amoxicillin/clavulanic acid are the most recommended first-choice antibiotics.

    Besides antibiotics, vaginal estrogen therapy proves to be useful for postmenopausal women who have recurrent Urinary Tract Infections. Furthermore, numerous supplements are used to prevent UTIs in some patients, though there is little supporting evidence for many of these, and recommendation is based more anecdotally.

    However, improper treatment approaches appear to be the central challenge prevalent in the Uncomplicated Urinary Tract Infections Therapy market. It adds to the healthcare expenditure, increases risks of potential side effects, and also results in antibiotic resistance limiting the usage of other available options. 

    Access the sample copy of the report for more details @ Uncomplicated Urinary Tract Infection Market Unmet Needs

    Uncomplicated Urinary Tract Infection Market Dynamics

    The Uncomplicated Urinary Tract Infection drug market is forecasted to gravitate towards the growth quadrant in the coming decade accredited to an influx of several pharma companies in the space vying to develop novel therapeutics agents and get a hold of substantial uUTI market share. Key players, such as GlaxoSmithKline, Fimbrion Therapeutics, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, and several others, are developing novel therapies and pushing the Uncomplicated Urinary Tract Infection market size growth forward.

    Furthermore, emerging therapies coupled with increasing Uncomplicated Urinary Tract incidence is escalating the research and development endeavors in this segment leading to a substantial increase in competition and overall market size. Retrospectively, the past two decades witnessed a lot of activity and some noteworthy advancements toward the development and increased uptake of UTI vaccines as well as drugs to tackle antibiotics resistance. 

    For instance, Sulopenem is currently targeting the quinolone non-susceptible pool in the pivotal trial. Previously sulopenem has missed the primary endpoint in the SURE-2 phase 3 clinical trial of oral and IV sulopenem in complicated urinary tract infection (cUTI). However, with SURE-1 achieving its primary goal, Iterum Therapeutics has identified a population (i.e., Quinolone non-susceptible uUTI) in which the drug seems to work and win approval. Oral sulopenem is currently under the FDA review for uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen and has a PDUFA goal date of July 25, 2021.

    Contrariwise, antibiotic resistance, which on one side continues to be a blockade in the compliance of available antibiotics, on the other side it also opens new avenues for pharma players to bring novel antibiotics on the table to meet the growing demand. 

    Drop by to learn more about the future market trends @ Uncomplicated Urinary Tract Infection Market Landscape and Forecast 

    Uncomplicated Urinary Tract Infection Pipeline Therapies Gepotidacin (GSK2140944): GlaxoSmithKlineGSK3882347: GlaxoSmithKlineSulopenem: Iterum TherapeuticsUromune (MV140): InmunotekExPEC10V (VAC52416/JNJ-69968054): Janssen PharmaceuticalsExPEC4V (JNJ-63871860): Janssen Pharmaceuticals

    Check out for more @ Uncomplicated Urinary Tract Infection Drug Pipeline Therapies 

    Scope of the Uncomplicated Urinary Tract Infection Market Report 

    Coverage: 7MM (the US, EU5, and Japan)

    Study Period: 2018-30

    Key Companies: GlaxoSmithKline, Fimbrion Therapeutics, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, and others. 

    Key Uncomplicated Urinary Tract Infection Pipeline Therapies: Gepotidacin, GSK3882347, Uromune, ExPEC10V, and others. 

    Uncomplicated Urinary Tract Infection Market Segmentation: By Geography, By Uncomplicated Urinary Tract Infection Therapies

    Analysis: Comparative and conjoint analysis of Uncomplicated Urinary Tract Infection emerging therapies

    Tools used: SWOT analysis, Conjoint Analysis, Porter’s Five Forces, PESTLE analysis, BCG Matrix analysis methods.

    Case Studies

    KOL’s Views

    Analyst’s Views

    Interested in knowing which pharma company is expected to establish a major hold in the market? Drop your query at [email protected] 

    Table of Contents 

    1

    Key Insights

    2

    Uncomplicated Urinary Tract Infection Market Report Introduction

    3

    Uncomplicated Urinary Tract Infection Market Overview at a Glance

    4

    Executive Summary of Uncomplicated Urinary Tract Infection

    5

    Disease Background and Overview

    6

    Algorithm for Diagnosis of Uncomplicated Urinary Tract Infection 

    7

    Patient Journey

    8

    Prevention

    9

    Uncomplicated Urinary Tract Infection Epidemiology and Patient Population

    10

    Treatment Algorithm, Current Treatment, and Medical Practices

    11

    Uncomplicated Urinary Tract Infection Epidemiology and Patient Population

    10

    Country Wise-Epidemiology of Uncomplicated Urinary Tract Infection

    12

    Uncomplicated Urinary Tract Infection Treatment 

    13

    Unmet Needs

    14

    Key Endpoints of Uncomplicated Urinary Tract Infection Treatment

    15

    Uncomplicated Urinary Tract Infection Emerging Therapies

    16

    Uncomplicated Urinary Tract Infection: 7 Major Market Analysis

    17

    Uncomplicated Urinary Tract Infection Market Unmet Needs 

    18

    Uncomplicated Urinary Tract Infection Market Access and Reimbursement

    19

    Uncomplicated Urinary Tract Infection Market Drivers

    20

    Uncomplicated Urinary Tract Infection Market Barriers

    21

    SWOT Analysis

    21

    KOL Reviews

    22

    Appendix

    23

    DelveInsight Capabilities

    24

    Disclaimer

    25

    About DelveInsight

    Discover more @ Uncomplicated Urinary Tract Infection Market Forecast 

    Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions 

    Related Reports

    Complicated Urinary Tract Infections Market

    DelveInsight’s “Complicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast-2030” report.

    Stress Urinary Incontinence Market

    DelveInsight’s “Stress Urinary Incontinence – Market Insights, Epidemiology, and Market Forecast-2030” report.

    Urinary Incontinence Market

    DelveInsight’s “Urinary Incontinence – Market Insights, Epidemiology, and Market Forecast-2030” report

    Urinary Catheters Market

    DelveInsight’s ‘Urinary Catheters -Market Insights, Competitive Landscape and Market Forecast – 2026’ report. Have a holistic analysis of key companies featured in the space including, Baxter, Asahi Kasei Corporation, Fresenius Medical Care AG & Co. KGaA, Cantel Medical, Rockwell Medical, JMS Co. Ltd., Teleflex Incorporated, B. Braun Melsungen AG, NIPRO, HEMOCLEAN CO., LTD., Quanta, Outset Medical, Inc., and others. 

    Urinary Flow Meter Devices Market

    DelveInsight’s ‘Urinary Flow Meter Devices -Market Insights, Competitive Landscape and Market Forecast – 2026’ report. Have a holistic analysis of key companies featured in the space including, LABORIE, SCHIPPERS-MEDIZINTECHNIK, tic Medizintechnik GmbH & Co. KG, EV.SERVICE ITALIA SRL, Aymed Group of Companies, CellSonic Medical, NOVAMEDTEK, Medispec Ltd., and others.

    Related Blogs

    Acute Kidney Injury Market and Emerging Therapies in the Pipeline

    Discover which Oncology player is set to emerge as the leader in the Prostate Cancer Market 

    Medical Marijuana and Clinical Trials Ongoing for Different Indications 

    About DelveInsight

    DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

    For more insights, visit Pharma, Healthcare, and Biotech News 

    Contact Us

    Shruti Thakur  [email protected]  +1(919)321-6187  www.delveinsight.com

    SOURCE DelveInsight Business Research, LLP

    Antibiotics For UTI Treatment: What Are My Options? – Drugs.com

    What Are the Best Antibiotics for Urinary Tract infection? – GoodRx

    antibiotics for uti

    About Post Author

    coolpraveenbds

    hi this is Dr Praveen from apple dental clinic varanasi and here teeth problems are solved with an affordable price.
    Facebook Comments Box

    By coolpraveenbds

    hi this is Dr Praveen from apple dental clinic varanasi and here teeth problems are solved with an affordable price.

    Average Rating

    5 Star
    100%
    4 Star
    0%
    3 Star
    0%
    2 Star
    0%
    1 Star
    0%

    2 thoughts on “This Week’s Top Stories About Antibiotics For Uti

    Leave a Reply

    Your email address will not be published. Required fields are marked *